Shepherd Kaplan Krochuk’s Trinity Biotech TRIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q1
Sell
-7,280
Closed -$186K 274
2017
Q4
$186K Sell
7,280
-5,587
-43% -$144K 0.12% 190
2017
Q3
$361K Sell
12,867
-600
-4% -$16.7K 0.3% 99
2017
Q2
$404K Sell
13,467
-2,224
-14% -$63K 0.24% 95
2017
Q1
$468K Hold
15,691
0.24% 86
2016
Q4
$543K Buy
15,691
+5,303
+51% +$183K 0.15% 79
2016
Q3
$687K Sell
10,388
-221
-2% -$13.8K 0.14% 89
2016
Q2
$602K Hold
10,609
0.15% 91
2016
Q1
$619K Sell
10,609
-10,707
-50% -$568K 0.19% 83
2015
Q4
$1.25M Buy
21,316
+287
+1% +$16.9K 0.33% 48
2015
Q3
$1.2M Sell
21,029
-4,073
-16% -$328K 0.32% 50
2015
Q2
$2.27M Sell
25,102
-1,185
-5% -$103K 0.43% 37
2015
Q1
$2.53M Sell
26,287
-1,965
-7% -$182K 0.45% 33
2014
Q4
$2.47M Buy
28,252
+1,600
+6% +$138K 0.4% 50
2014
Q3
$2.44M Buy
26,652
+58
+0.2% +$6.28K 0.31% 50
2014
Q2
$3.06M Hold
26,594
0.32% 49
2014
Q1
$3.22M Sell
26,594
-1,781
-6% -$233K 0.37% 45
2013
Q4
$3.57M Sell
28,375
-2,825
-9% -$339K 0.45% 39
2013
Q3
$3.39M Sell
31,200
-2,007
-6% -$196K 0.55% 34
2013
Q2
$2.8M Buy
+33,207
New +$2.75M 0.55% 34

Other funds holding TRIB

Shepherd Kaplan Krochuk's TRIB Position: Q1 2018 in Review

Shepherd Kaplan Krochuk sold out of Trinity Biotech (TRIB) in Q1 2018, closing a stake of 7,280 shares — an estimated $186K sold.

Shepherd Kaplan Krochuk first reported a position in TRIB in Q2 2013 and held it in 19 quarters. The position peaked at $3.57M in Q4 2013. 45 funds tracked by Wall St. Rank hold TRIB as of Q1 2018.

  • Shepherd Kaplan Krochuk reported no remaining Trinity Biotech position as of Q1 2018 after selling out during the quarter.
  • Shepherd Kaplan Krochuk sold 7,280 Trinity Biotech shares in Q1 2018, an estimated $186K.
  • Shepherd Kaplan Krochuk first reported a position in Trinity Biotech in Q2 2013 and held it in 19 quarters.
  • Shepherd Kaplan Krochuk's Trinity Biotech position peaked at $3.57M in Q4 2013.
  • 45 funds tracked by Wall St. Rank held Trinity Biotech as of Q1 2018.

Based on Shepherd Kaplan Krochuk's 13F filing for Q1 2018, filed 11 May 2018.